155 episodes
The Long Run with Luke Timmerman Timmerman Report
-
- Science
-
-
4.0 • 1 Rating
-
"The Long Run"
Antarctic explorer Ernest Shackleton would appreciate today's biotech. Scientific entrepreneurs of the 21st century must be ready for what Shackleton called the “hazardous journey, bitter cold, long months of complete darkness, constant danger, safe return doubtful, honor and recognition in case of success.” Today, the men and women who strive to apply science for the betterment of human health have a historic opportunity. They need stamina and resilience to achieve something meaningful. Biotech’s relationship with the society that sustains it has never been more tenuous.
Join host Luke Timmerman for in-depth, thought-provoking conversations with biotech newsmakers pursuing these great opportunities of the 21st century.
-
Ep157: Vineeta Agarwala of A16Z on Investing in AI for Drug Discovery
Vineeta Agarwala, general partner at A16Z's Bio & Health fund, on investing in AI for drug discovery.
-
Ep156: David Liu on New Tools and Techniques for Biology
David Liu, professor of chemistry at Harvard University and co-founder of multiple biotech companies, including Beam Therapeutics and Prime Medicine.
-
Ep155: Valerie Daggett on Early Detection, and Treatment, of Alzheimer's
Valerie Daggett, founder and CEO of Seattle-based AltPep, on early detection and treatment of Alzheimer's.
-
Ep154: Robert Ang on CRISPR to Protect Bone Marrow & Attack Cancer
Robert Ang, CEO of Cambridge, Mass.-based Vor Bio, on using CRISPR gene editing to alter bone marrow transplants and improve treatment of acute myeloid leukemia.
-
Ep153: Rick Young on Studying Gene Expression for Drug Discovery
Rick Young, professor at MIT and co-founder of Syros Pharmaceuticals, CAMP4 Therapeutics, Omega Therapeutics, and Dewpoint Therapeutics, on studying gene expression for drug discovery.
-
Ep152: Jens Eckstein on Investing in Healthy Aging
Jens Eckstein, investment partner at Hevolution Foundation, on investing in healthy aging.